



**Australian Government**  
**Repatriation Medical Authority**

**Statement of Principles**  
**concerning**  
**MACULAR DEGENERATION**  
**(Balance of Probabilities)**  
**(No. 60 of 2018)**

---

The Repatriation Medical Authority determines the following Statement of Principles under subsection 196B(3) of the *Veterans' Entitlements Act 1986*.

Dated 22 June 2018

The Common Seal of the  
Repatriation Medical Authority  
was affixed to this instrument  
at the direction of:

A handwritten signature in black ink, appearing to read 'N. Saunders'.

Professor Nicholas Saunders AO  
Chairperson

# Contents

1	Name .....	3
2	Commencement .....	3
3	Authority .....	3
4	Repeal .....	3
5	Application.....	3
6	Definitions .....	3
7	Kind of injury, disease or death to which this Statement of Principles relates .....	3
8	Basis for determining the factors .....	4
9	Factors that must exist.....	4
10	Relationship to service .....	5
11	Factors referring to an injury or disease covered by another Statement of Principles .....	6
<b>Schedule 1 - Dictionary .....</b>		<b>7</b>
1	Definitions .....	7

**1 Name**

This is the Statement of Principles concerning *macular degeneration (Balance of Probabilities)* (No. 60 of 2018).

**2 Commencement**

This instrument commences on 23 July 2018.

**3 Authority**

This instrument is made under subsection 196B(3) of the *Veterans' Entitlements Act 1986*.

**4 Repeal**

The Statement of Principles concerning macular degeneration No. 14 of 2009 (Federal Register of Legislation No. F2009L01581) made under subsection 196B(3) of the VEA is repealed.

**5 Application**

This instrument applies to a claim to which section 120B of the VEA or section 339 of the *Military Rehabilitation and Compensation Act 2004* applies.

**6 Definitions**

The terms defined in the Schedule 1 - Dictionary have the meaning given when used in this instrument.

**7 Kind of injury, disease or death to which this Statement of Principles relates**

- (1) This Statement of Principles is about macular degeneration and death from macular degeneration.

*Meaning of macular degeneration*

- (2) For the purposes of this Statement of Principles, macular degeneration:
- (a) means a group of degenerative diseases of the macula of the eye that may cause progressive, painless loss of central vision; and
  - (b) includes:
    - (i) early macular degeneration; and
    - (ii) late macular degeneration; and
  - (c) excludes toxic retinopathy.

Note: *early macular degeneration* and *late macular degeneration* are defined in the Schedule 1 – Dictionary.

### *Death from macular degeneration*

- (3) For the purposes of this Statement of Principles, macular degeneration, in relation to a person, includes death from a terminal event or condition that was contributed to by the person's macular degeneration.

Note: *terminal event* is defined in the Schedule 1 – Dictionary.

## **8 Basis for determining the factors**

On the sound medical-scientific evidence available, the Repatriation Medical Authority is of the view that it is more probable than not that macular degeneration and death from macular degeneration can be related to relevant service rendered by veterans or members of the Forces under the VEA, or members under the MRCA.

Note: *MRCA*, *relevant service* and *VEA* are defined in the Schedule 1 – Dictionary.

## **9 Factors that must exist**

At least one of the following factors must exist before it can be said that, on the balance of probabilities, macular degeneration or death from macular degeneration is connected with the circumstances of a person's relevant service:

- (1) smoking at least 15 pack-years of cigarettes, or the equivalent thereof in other tobacco products, before the clinical onset of macular degeneration, and:
  - (a) smoking commenced at least five years before the clinical onset of macular degeneration; and
  - (b) where smoking has ceased, the clinical onset of macular degeneration has occurred within 20 years of cessation;

Note: *pack-years of cigarettes, or the equivalent thereof in other tobacco products* is defined in the Schedule 1 - Dictionary.

- (2) consuming a cumulative total of at least 20 kilograms of alcohol in a continuous period of two years, within the five years before the clinical onset of macular degeneration;

Note: Alcohol consumption is calculated utilising the Australian Standard of ten grams of alcohol per standard alcoholic drink.

- (3) being obese for at least the five years before the clinical onset of macular degeneration;

Note: *being obese* is defined in the Schedule 1 - Dictionary.

- (4) having chronic kidney disease within the five years before the clinical onset of macular degeneration;

Note: *chronic kidney disease* is defined in the Schedule 1 - Dictionary.

(5) smoking at least 15 pack-years of cigarettes, or the equivalent thereof in other tobacco products, before the clinical worsening of macular degeneration, and:

- (a) smoking commenced at least five years before the clinical worsening of macular degeneration; and
- (b) where smoking has ceased, the clinical worsening of macular degeneration has occurred within 20 years of cessation;

Note: *pack-years of cigarettes, or the equivalent thereof in other tobacco products* is defined in the Schedule 1 - Dictionary.

(6) consuming a cumulative total of at least 20 kilograms of alcohol in a continuous period of two years, within the five years before the clinical worsening of macular degeneration;

Note: Alcohol consumption is calculated utilising the Australian Standard of ten grams of alcohol per standard alcoholic drink.

(7) being obese for at least the five years before the clinical worsening of macular degeneration;

Note: *being obese* is defined in the Schedule 1 - Dictionary.

(8) having chronic kidney disease within the five years before the clinical worsening of macular degeneration;

Note: *chronic kidney disease* is defined in the Schedule 1 - Dictionary.

(9) for clinical worsening of wet macular degeneration manifesting as subretinal haemorrhage only, having anticoagulant therapy or thrombolytic therapy, within the seven days before the clinical worsening of macular degeneration;

Note: *anticoagulant therapy* and *thrombolytic therapy* are defined in the Schedule 1 - Dictionary.

(10) inability to obtain appropriate clinical management for macular degeneration.

## **10 Relationship to service**

- (1) The existence in a person of any factor referred to in section 9, must be related to the relevant service rendered by the person.
- (2) The factors set out in subsections 9(5) to 9(10) apply only to material contribution to, or aggravation of, macular degeneration where the person's macular degeneration was suffered or contracted before or during (but did not arise out of) the person's relevant service.

**11 Factors referring to an injury or disease covered by another Statement of Principles**

In this Statement of Principles:

- (1) if a factor referred to in section 9 applies in relation to a person; and
- (2) that factor refers to an injury or disease in respect of which a Statement of Principles has been determined under subsection 196B(3) of the VEA;

then the factors in that Statement of Principles apply in accordance with the terms of that Statement of Principles as in force from time to time.

# Schedule 1 - Dictionary

Note: See Section 6

## 1 Definitions

In this instrument:

***an abnormality of kidney structure or function*** means:

- (a) having a glomerular filtration rate of less than 60 mL/min/1.73 m<sup>2</sup>; or
- (b) having kidney damage, as evidenced by renal biopsy, imaging studies, albuminuria, urinary sediment abnormalities or other markers of abnormal renal function; or
- (c) having had a kidney transplant.

***anticoagulant therapy*** means therapeutic administration of a pharmacological agent which suppresses, delays or nullifies blood coagulation (such as heparin, warfarin or dicumarol), but excludes antiplatelet therapy (such as aspirin, clopidogrel, ticlopidine or monoclonal antibodies and recombinant and chemically synthesised peptides that block platelet adhesion or aggregation).

***being obese*** means having a Body Mass Index (BMI) of 30 or greater.

Note: ***BMI*** is also defined in the Schedule 1 – Dictionary.

***BMI*** means  $W/H^2$  where:

W is the person's weight in kilograms; and  
H is the person's height in metres.

***chronic kidney disease*** means an abnormality of kidney structure or function that has been present for at least three months.

Note: ***an abnormality of kidney structure or function*** is also defined in the Schedule 1 – Dictionary.

***early macular degeneration*** means:

- (a) drusen of at least medium size ( $\geq 63 \mu\text{m}$ ); or
- (b) retinal pigmentary abnormalities; or
- (c) soft indistinct or reticular drusen.

***late macular degeneration*** means dry macular degeneration (geographic atrophy) or wet macular degeneration.

Note: ***wet macular degeneration*** is also defined in the Schedule 1 – Dictionary.

***macular degeneration***—see subsection 7(2).

***MRCA*** means the *Military Rehabilitation and Compensation Act 2004*.

***pack-years of cigarettes, or the equivalent thereof in other tobacco products*** means a calculation of consumption where one pack-year of cigarettes equals 20 tailor-made cigarettes per day for a period of one calendar year, or 7 300 cigarettes. One tailor-made cigarette approximates one gram of tobacco or one gram of cigar or pipe tobacco by weight. One pack-year of tailor-made cigarettes equates to 7.3 kilograms of smoking tobacco by weight. Tobacco

products mean cigarettes, pipe tobacco or cigars, smoked alone or in any combination.

**relevant service** means:

- (a) eligible war service (other than operational service) under the VEA;
- (b) defence service (other than hazardous service and British nuclear test defence service) under the VEA; or
- (c) peacetime service under the MRCA.

Note: **MRCA** and **VEA** are also defined in the Schedule 1 - Dictionary.

**terminal event** means the proximate or ultimate cause of death and includes the following:

- (a) pneumonia;
- (b) respiratory failure;
- (c) cardiac arrest;
- (d) circulatory failure; or
- (e) cessation of brain function.

**thrombolytic therapy** means therapeutic administration of a pharmacological agent which breaks up or dissolves blood clots (such as streptokinase or tissue plasminogen activator).

**VEA** means the *Veterans' Entitlements Act 1986*.

**wet macular degeneration** means choroidal neovascularisation and retinal angiomatous proliferation. It is also known as neovascular or exudative macular degeneration. Complications include subretinal haemorrhage.